Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR(+)/HER2(−) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

PURPOSE: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive (HR(+)), HER2-negative (HER2(−)) advanced breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yen-Shen, Im, Seock-Ah, Colleoni, Marco, Franke, Fabio, Bardia, Aditya, Cardoso, Fatima, Harbeck, Nadia, Hurvitz, Sara, Chow, Louis, Sohn, Joohyuk, Lee, Keun Seok, Campos-Gomez, Saul, Villanueva Vazquez, Rafael, Jung, Kyung Hae, Babu, K. Govind, Wheatley-Price, Paul, De Laurentiis, Michelino, Im, Young-Hyuck, Kuemmel, Sherko, El-Saghir, Nagi, O'Regan, Ruth, Gasch, Claudia, Solovieff, Nadia, Wang, Craig, Wang, Yongyu, Chakravartty, Arunava, Ji, Yan, Tripathy, Debu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377723/
https://www.ncbi.nlm.nih.gov/pubmed/34965945
http://dx.doi.org/10.1158/1078-0432.CCR-21-3032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377723/
https://www.ncbi.nlm.nih.gov/pubmed/34965945
http://dx.doi.org/10.1158/1078-0432.CCR-21-3032

Ejemplares similares